Ralf C. Bargou

19.4k total citations · 8 hit papers
178 papers, 11.7k citations indexed

About

Ralf C. Bargou is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ralf C. Bargou has authored 178 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Oncology, 75 papers in Molecular Biology and 63 papers in Hematology. Recurrent topics in Ralf C. Bargou's work include CAR-T cell therapy research (60 papers), Multiple Myeloma Research and Treatments (48 papers) and Monoclonal and Polyclonal Antibodies Research (35 papers). Ralf C. Bargou is often cited by papers focused on CAR-T cell therapy research (60 papers), Multiple Myeloma Research and Treatments (48 papers) and Monoclonal and Polyclonal Antibodies Research (35 papers). Ralf C. Bargou collaborates with scholars based in Germany, United States and Italy. Ralf C. Bargou's co-authors include Maria-Elisabeth Goebeler, Peter Kufer, Patrick A. Baeuerle, Bernd Dörken, Kurt Bommert, Markus Y. Mapara, Thorsten Stühmer, Manik Chatterjee, Hermann Einsele and Gerhard Zugmaier and has published in prestigious journals such as Science, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Ralf C. Bargou

171 papers receiving 11.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

2008 798 citations Ralf C. Bargou, Eugen Leo et al. profile →
Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

1997 638 citations Ralf C. Bargou, Kurt Bommert et al. profile →
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin

2005 507 citations Qingqing Ding, Weiya Xia et al. Molecular Cell profile →
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

2014 488 citations Max S. Topp, Nicola Gökbuget et al. profile →
T cell-engaging therapies — BiTEs and beyond

2020 411 citations Maria-Elisabeth Goebeler, Ralf C. Bargou profile →
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

2016 280 citations Julia Stieglmaier, Dirk Nagorsen et al. Blood profile →
Bispecific and multispecific antibodies in oncology: opportunities and challenges

2024 65 citations Maria-Elisabeth Goebeler, Ralf C. Bargou et al. profile →

Peers

Countries citing papers authored by Ralf C. Bargou

Since Specialization

Citations

This map shows the geographic impact of Ralf C. Bargou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf C. Bargou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf C. Bargou more than expected).

Fields of papers citing papers by Ralf C. Bargou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf C. Bargou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf C. Bargou. The network helps show where Ralf C. Bargou may publish in the future.

Co-authorship network of co-authors of Ralf C. Bargou

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf C. Bargou. A scholar is included among the top collaborators of Ralf C. Bargou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf C. Bargou. Ralf C. Bargou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	YBX1 modulates humoral immunity through post-transcriptional regulation in B cells 2025 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), Ralf C. Bargou, (unknown), (unknown)	0
2	Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma 2024 ·Blood Cancer Journal ·(unknown), Thorsten Stühmer, Martin Schreder, Torsten Steinbrunn, Martina Rudelius, Franziska Jundt, Regina Ebert, Tanja Nicole Hartmann, Ralf C. Bargou, Andreas Rosenwald, Ellen Leich	2
3	Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch 2024 ·npj Precision Oncology ·Barbara Deschler-Baier, (unknown), Matthias Kroiß, Manik Chatterjee, Daniel Gündel, (unknown), Alexander Kerscher, Volker Kunzmann, Silke Appenzeller, Katja Maurus, Andreas Rosenwald, Ralf C. Bargou, Elena Hartmann, Vivek Venkataramani	0
4	Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures 2023 ·Cancers ·(unknown), Philipp E. Hartrampf, Philip Kollmannsberger, Antonio Giovanni Solimando, Svenja Meierjohann, Hubert Kübler, Ralf C. Bargou, Bastian Schilling, Sebastian E. Serfling, Andreas K. Buck, Rudolf A. Werner, Constantin Lapa, Markus Krebs	4
5	Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate 2023 ·Pharmaceuticals ·Daniela Brünnert, (unknown), Pankaj Goyal, (unknown), (unknown), (unknown), (unknown), Doris Feineis, Ralf C. Bargou, Andreas Schlösser, Gerhard Bringmann, Manik Chatterjee	2
6	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events 2019 ·Cancer Research ·Matthias Klinger, Gerhard Zugmaier, (unknown), Maria-Elisabeth Goebeler, Christian Brandl, Matthias Stelljes, Hans Lassmann, Arend von Stackelberg, Ralf C. Bargou, Peter Kufer	51
7	Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma 2019 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Daniela Brünnert, Marianne Kraus, Thorsten Stühmer, (unknown), (unknown), Pankaj Goyal, Christoph Driessen, Ralf C. Bargou, Manik Chatterjee	13
8	Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia breakdown → 2018 ·Blood ·Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, H. Diedrich, Max S. Topp, Monika Brüggemann, Heinz‐August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou	516
9	Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules 2013 ·Blood Cancer Journal ·Ellen Leich, Susann Weißbach, Hans‐Ulrich Klein, (unknown), Jordan Pischimarov, Thorsten Stühmer, Manik Chatterjee, Torsten Steinbrunn, Christian Langer, Martin Eilers, Stefan Knop, Hermann Einsele, Ralf C. Bargou, Andreas Rosenwald	43
10	The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival 2012 ·Leukemia ·Kurt Bommert, (unknown), Ellen Leich, (unknown), Daniel J. Murphy, Christian Langer, R. Moll, Siegfried Janz, Anja Mottok, Susann Weißbach, Andreas Rosenwald, Ralf C. Bargou	43
11	Integrin-linked kinase is dispensable for multiple myeloma cell survival 2012 ·Leukemia Research ·Torsten Steinbrunn, Daniela Siegmund, Mindaugas Andrulis, (unknown), K. Martin Kortüm, Hermann Einsele, Harald Wajant, Ralf C. Bargou, Thorsten Stühmer	10
12	A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma 2008 ·European Journal Of Haematology ·M von Lilienfeld-Toal, Corinna Hahn‐Ast, (unknown), Florian Hoffmann, Ralph Naumann, Ralf C. Bargou, Gordon Cook, Axel Glasmacher	56
13	Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells 2008 ·Leukemia Research ·(unknown), (unknown), Christian Brandl, Nadja Prang, Ralf Lutterbuese, (unknown), JoAnn Suzich, Mathias Locher, Peter A. Kiener, Peter Kufer, Robert Hofmeister, Patrick A. Baeuerle, Ralf C. Bargou	58
14	Signalling and survival pathways in multiple myeloma 2006 ·European Journal of Cancer ·Kurt Bommert, Ralf C. Bargou, Thorsten Stühmer	128
15	Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin breakdown → 2005 ·Molecular Cell ·Qingqing Ding, Weiya Xia, (unknown), Jer-Yen Yang, Dung‐Fang Lee, Jiahong Xia, Geoffrey Bartholomeusz, Yan Li, Yong Pan, Zheng Li, Ralf C. Bargou, Jun Qin, Chien‐Chen Lai, Fuu‐Jen Tsai, Chang‐Hai Tsai, Mien‐Chie Hung	507
16	T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct 2005 ·Cancer Immunology Immunotherapy ·Bernd Schlereth, Cornelia Quadt, Torsten Dreier, Peter Kufer, Grit Lorenczewski, Nadja Prang, Christian Brandl, (unknown), KATHY E. COBB, Kathleen M. Brasky, Eugen Leo, Ralf C. Bargou, Krishna K. Murthy, Patrick A. Baeuerle	77
17	PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells 2004 ·Leukemia ·Suzanne Lentzsch, Manik Chatterjee, (unknown), Kurt Bommert, (unknown), Bernd Dörken, Ralf C. Bargou	100
18	T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct 2003 ·The Journal of Immunology ·Torsten Dreier, Patrick A. Baeuerle, Iduna Fichtner, M. Grün, Bernd Schlereth, Grit Lorenczewski, Peter Kufer, Ralf Lutterbüse, Gert Riethmüller, P. Gjörstrup, Ralf C. Bargou	155
19	Activation and activation‐induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO‐1) ligand expression and function 1997 ·European Journal of Immunology ·Peter T. Daniel, (unknown), Markus Y. Mapara, Kurt Bommert, Ralf C. Bargou, Bernd Dörken	31
20	Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice. 1993 ·The Journal of Experimental Medicine ·Ralf C. Bargou, Markus Y. Mapara, Christian Zugck, Peter T. Daniel, Michael Pawlita, Hartmut Döhner, Bernd Dörken	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact